Sign in
Taking people in GermanyPhase 2

Stool-based capsules for immune activation in people with cirrhosis and fluid buildup

Tests the safety of fecal microbiota capsules in adults with cirrhosis and ascites.

Key facts

Who runs it
Universitaetsklinikum Aachen AöR
Where
Aachen, GermanySee the site
Registry title
Encapsulated Fecal Microbiota Transfer to Treat Immune Activation in Patients with Cirrhosis and Ascites (TransImmune) – A randomized, double-blind, placebo-controlled phase IIa clinical pilot study
Status
Recruiting
Phase
Phase 2
People taking part
24 people, planned
Started
1 Aug 2025
Expected to end
31 Mar 2027
Type of study
Interventional
Record updated
22 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with cirrhosis (scarring of the liver) and fluid in the belly (ascites). It tests the safety of capsules with stool bacteria from donors (FMT) against placebo.

Age
18 to 70 years
Sex
All sexes
Disease stage
Cirrhosis of any cause, with ascites. Fluid must have been drained or sampled from the belly within the last 30 days. MELD score must not be above 20. Acute-on-chronic liver failure grade 2 or higher is not allowed.
Earlier treatment
No systemic antibiotics in the 7 days before joining, except stable doses of norfloxacin or rifaximin. No immune-modifying drugs now or in the 90 days before joining. No investigational drug in another study in the last 30 days.

Main reasons for not taking part

  • Active cancer, or past cancer not fully treated (except non-melanoma skin cancer)
  • Active bacterial infection at the start
  • Known immune deficiency, such as HIV infection
  • Pregnant or breastfeeding
  • Expected to live less than six months

The registry criteria, word for word

Show all 24 criteriaShow less

Who can take part

  • Subject has cirrhosis of any etiology based on clinical standard criteria, imaging findings, and/or histology
  • Subject is diagnosed with ascites and has undergone paracentesis or diagnostic ascitic tap within the last 30 days prior to study inclusion
  • Subject age is between 18 and 70 years at the time of study inclusion
  • Subject is able to swallow the Investigational Medicinal Product (IMP) Fecal Microbiota Transfer capsules or placebo
  • Subject is mentally and physically able to understand the significance and scope of the study and to comply with the study protocol
  • A written informed consent form has been signed prior to participation in the study

Who cannot take part

  • Subject has received systemic antibiotics within 7 days prior to study inclusion, except for stable doses of norfloxacin or rifaximin
  • Subject receives treatment with immunomodulatory drugs (prednisolone, prednisone, methylprednisolone, hydrocortisone, dexamethasone, azathioprine, mercaptopurine, tacrolimus, mycophenolate, cyclosporine, sirolimus, everolimus, hydroxychloroquine, leflunomide, methotrexate, infliximab, adalimumab, etanercept, rituximab, anakinra, tofacitinib, upadacitinib, natalizumab, basiliximab), currently or within 90 days prior to study inclusion
  • Study participation is, at the discretion of the investigator, an unacceptable risk due to pre-existing or concomitant disease or due to the patient's general underlying condition
  • Subject has received an investigational drug in another study within the last 30 days before study inclusion
  • Concurrent participation in another clinical intervention study
  • Subject has acute-on-chronic liver failure (ACLF) grade 2 or higher according to the EASL-CLIF Consortium definition
  • Subject has active malignancy or history of malignancy, which was not curatively treated (excluding non-melanoma skin cancer)
  • Subject has a history of hypersensitivity or allergies to the investigational capsule coating substances or to any compound of INTESTIFIX 001 or placebo
  • Subject has active bacterial infection at inclusion
  • Subject has known primary immunodeficiency (e.g., Bruton disease or common variable immunodeficiency) or secondary immunodeficiency (e.g., HIV infection)
  • There is a current or past medically relevant disease or treatment that could influence the evaluation of the study
  • Subject has Model for End-Stage Liver Disease (MELD) score >20
  • Subject has an expected lack of compliance
  • Subject has a life expectancy of less than six months
  • Subject is pregnant or breastfeeding
  • Subject is not willing to take adequately safe contraceptive measures
  • Subject is institutionalized due to an official or court order
  • Subject is in a dependent relationship or employment relationship with the sponsor or investigator

Where in Germany

  • Universitaetsklinikum Aachen AöRAachen, GermanyTaking people

About the trial

What the trial wants to find out

To evaluate the safety of FMT capsules for the treatment of immune activation in patients with cirrhosis and ascites.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
Encapsulated Fecal Microbiota Transfer to Treat Immune Activation in Patients with Cirrhosis and Ascites (TransImmune) – A randomized, double-blind, placebo-controlled phase IIa clinical pilot study
Plain-language title
Stool-based capsules for immune activation in people with cirrhosis and fluid buildupGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
22 July 2026